X0306 4 2017-03-01 0 0001348649 CoLucid Pharmaceuticals, Inc. CLCD 0000059478 LILLY ELI & CO LILLY CORPORATE CENTER INDIANAPOLIS IN 46285 0 0 1 0 0001695312 ProCar Acquisition Corp LILLY CORPORATE CENTER INDIANAPOLIS IN 46285 0 0 1 0 Common Stock, par value $0.001 2017-03-01 4 J 0 19285108 46.50 A 100 D On March 1, 2017, Eli Lilly and Company ("Parent") and ProCar Acquisition Corporation ("Merger Sub") completed the transactions contemplated by the Agreement and Plan of Merger, dated as of January 17, 2017, by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Parent and Merger Sub (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly-owned subsidiary of Parent (the "Surviving Corporation"). At the effective time of the Merger, the outstanding shares of common stock of Merger Sub were converted into and became shares of the Surviving Corporation. /s/ Derica W. Rice, Executive Vice President and CFO, Eli Lilly and Company 2017-03-01 /s/ Darren J. Carroll, President, ProCar Acquisition Corporation 2017-03-01